Stanford Scientist's Implant Restores Vision for Blind Adults
A tiny prosthetic eye implant developed at Stanford University is enabling some adults with age-related macular degeneration to read, recognize faces, and engage in artistic activities.
A groundbreaking retinal implant, developed by Stanford University scientist Daniel Palanker, is restoring meaningful vision to blind adults. The PRIMA retinal implant system, smaller than a contact lens, has demonstrated significant success in European clinical trials, allowing patients to read, identify faces, and even create art.
The device targets age-related macular degeneration, a leading cause of blindness affecting approximately 1 million people in the U.S. Palanker, an ophthalmologist and electrical engineer, designed the implant as a 2-by-2-millimeter disc containing 370 photosensitive pixels. This microchip is surgically placed behind the retina.
Following implantation, patients wear specialized augmented-reality glasses equipped with a camera. This camera captures images and projects them as near-infrared light onto the implant. The implant's solar-powered pixels then convert this light into electrical signals that stimulate remaining retinal cells, transmitting visual information to the brain.
Clinical trial results published in The New England Journal of Medicine show that after months of training, 26 out of 32 participants experienced substantial vision improvements one year post-implantation. On average, their vision improved by five lines on a standard eye chart, with some individuals gaining as many as 12 lines. This advancement enables many to perform daily tasks that were previously impossible.
Science Corp., the company commercializing the technology, is seeking European regulatory approval this summer and is pursuing a humanitarian device exemption from the U.S. Food and Drug Administration to expedite the review process. Palanker highlighted the innovation of using light for both the implant's power and activation, eliminating the need for wires.
"Until now, people tried restoring sight and all they got were light and shapes," Palanker stated. "We succeeded, I think, because we properly encode information and the brain understands this information as vision."
The PRIMA system is also being adapted for other vision impairments, such as Stargardt disease, with future generations aiming for even higher resolution. This development marks a significant stride in the expanding field of vision restoration, which also includes gene therapy and stem cell treatments.
"The field has never ever been anywhere near as advanced as it is today," said Jason Menzo, CEO of the Foundation Fighting Blindness. "Just knowing there’s something out there, just the promise of the technology, whether an individual even gets the device, is lifting people’s spirits."